Effects of once‐weekly glucagon‐like peptide‐1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin‐angiotensin system

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2023-11, Vol.25 (11), p.3223-3234
• Main Authors: Kan, Mengfan, Fu, Hui, Xu, Yunsheng, Yue, Zhaodi, Du, Bingyu, Chen, Qiang, Wang, Xueyin, Yu, Shaohong, Zhang, Zhongwen
• Format: Article
• Language: English
• Subjects: Agonists; Angiotensin; Blood pressure; Cardiovascular disease; Cardiovascular diseases; Cholesterol; Clinical trials; Coronary artery disease; Coronary vessels; Diabetes; Diabetes mellitus (non-insulin dependent); GLP-1 receptor agonists; Glucagon; Heart diseases; Hemoglobin; Matrix metalloproteinase; Meta-analysis; Metalloproteinase; network pharmacology; once‐weekly GLP‐1 receptor agonists; Peptides; Renin; renin‐angiotensin system; Risk factors; type 2 diabetes mellitus; Vein & artery diseases
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.15219

Aim To investigate the potential mechanism of once‐weekly glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) in the treatment of type 2 diabetes mellitus (T2DM) complicated with coronary artery disease (CAD). Methods We searched both Chinese and English databases for randomized controlled trials related to once‐weekly GLP‐1 RA for T2DM complicated with CAD to verify the safety and efficacy of GLP‐1 RA. The underlying mechanism was analysed by network pharmacology. Results In total, 13 studies with 35 563 participants were included in the analysis. The pooled analysis found that dulaglutide, exenatide and semaglutide outperformed placebo in cardiovascular outcomes in patients with T2DM, with a significant reduction in the incidence of non‐fatal stroke (p